CLINICAL TRIALS PROFILE FOR MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002146 ↗	Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study	Completed	Astra USA	Phase 4	1969-12-31	To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet.
NCT00004399 ↗	Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	Completed	University of Utah	N/A	1995-09-01	OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004399 ↗	Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	Completed	FDA Office of Orphan Products Development	N/A	1995-09-01	OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004730 ↗	Magnesium Sulfate For Brain Injury	Completed	University of Washington	Phase 3	1998-08-01	The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.
NCT00007033 ↗	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease	Completed	Children's Hospital Medical Center, Cincinnati	N/A	2000-10-01	OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.
NCT00007033 ↗	Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease	Completed	National Center for Research Resources (NCRR)	N/A	2000-10-01	OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.
NCT00010634 ↗	Complementary Naturopathic Medicine for Periodontitis	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 2	1999-09-01	This study aims to assess selected naturopathic medicines for adult periodontitis and to identify variables that influence successful outcomes when traditional and alternative approaches to preventing and treating periodontal diseases are combined. Collaboration between Kaiser Permanente, Oregon Health Science University and the National College of Naturopathic Medicine provides an unsurpassed environment for such investigations. Periodontitis is a major cause of tooth loss and negatively impacts systemic health. The limitations of traditional periodontal treatment have compelled scientists and clinicians to investigate new remedies, and naturopathic medicine holds several promising interventions. Because they are used to improve elements of host resistance that are known to be important in periodontal health and disease, three naturopathic medicines are potential adjuncts in preventing and treating periodontitis. Connective tissue components are enzymatically degraded in periodontitis. In naturopathy, Connective Tissue Nutrient Formula (CTNF) (vitamins A, C and D, glucosamine sulfate, oligoproanthocyanindins, copper, zinc, manganese, boron, silicon, magnesium, and calcium) is prescribed specifically to enhance the integrity of key connective tissue elements and improve their resistance to degradation. Periodontitis begins when permeability of the oral sulcular epithelium permits pathogenic bacterial components to invade deeper periodontal connective tissues. In naturopathy, glutamine is prescribed to reduce oral-intestinal epithelial membrane permeability. Chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis during the stress response, is a risk factor for periodontitis. Adaptogenic herbs (AH) (Panax ginseng, Withania somnifera and Eleutherococcus senticosus) are prescribed by naturopathic physicians to reverse the impact of bacterial and psychosocial stressors. Because glutamine, CTNF and AH target pathophysiologic mechanisms known to underline periodontitis, they are compelling candidates in clinical and mechanistic investigations of complementary medicine approaches to the management of periodontitis. Kaiser Permanente adult periodontitis patients will serve as subjects and receive standard periodontal treatment. Three of the four randomly assigned groups will also receive supplements of glutamine, CTNF, or AH. We will determine the effects of these supplements on clinical outcomes (attachment loss, pocket depths, indicators of inflammation, plaque composition, need for periodontal surgery, acute periodontal problems, tooth loss). In addition to completing the battery of self-report measures (stress, coping, quality of life), study subjects will provide samples of blood, saliva, gingival cervicular fluid and bacterial dental plaque. These samples will be examined as part of the Laboratory Core to identify biologic and genetic characteristics that correlate with successful outcomes. Storage of portions of the samples will allow future examination of additional variables as part of the Developmental Projects carried out as the Craniofacial Complementary & Alternative Center is established and Phase III trials are undertaken.

Clinical Trial Conditions for Magnesium Sulfate In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention	Trials
Postoperative Pain	23
Magnesium Sulfate	18
Pain	11
Preeclampsia	11

Condition MeSH

Condition MeSH for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention	Trials
Pain, Postoperative	43
Pre-Eclampsia	28
Asthma	18
Obstetric Labor, Premature	17

Clinical Trial Locations for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location	Trials
United States	139
Egypt	105
Korea, Republic of	18
Brazil	17
Canada	16

Trials by US State

Trials by US State for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location	Trials
California	14
New York	11
Ohio	9
Illinois	8
Pennsylvania	8

Clinical Trial Progress for Magnesium Sulfate In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
PHASE4	17
PHASE3	12
PHASE2	10

Clinical Trial Status

Clinical Trial Status for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	164
Recruiting	80
Not yet recruiting	48

Clinical Trial Sponsors for Magnesium Sulfate In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor	Trials
Assiut University	48
Cairo University	23
Seoul National University Bundang Hospital	13

Sponsor Type

Sponsor Type for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor	Trials
Other	495
NIH	14
Industry	12

Last updated: May 21, 2026

Magnesium Sulfate in Dextrose 5% (MgSO4 in D5W) in Plastic Container: Clinical Trials Update, Market Analysis, and Forecast

Executive summary: Magnesium sulfate in dextrose 5% for intravenous (IV) infusion is an established critical-care therapy supplied as a solution in plastic containers. Publicly disclosed clinical-trial activity is limited under this exact marketed format/name, and the forecast is therefore driven by underlying indications (eclampsia/severe preeclampsia, hypomagnesemia, torsades de pointes, and obstetric magnesium therapy), hospital purchasing patterns, and competitive supply of generic IV solutions. A defensible forward view requires anchored demand proxies (births with preeclampsia/eclampsia, ICU magnesium use rates, and replacement/shortage-driven procurement) rather than trial-driven breakthrough dynamics.

What clinical trials exist for Magnesium Sulfate in Dextrose 5% in plastic containers?

Direct format-specific trials (MgSO4 in D5W, plastic container)

• Public clinical trial disclosures typically group magnesium sulfate IV trials by active ingredient and indication (magnesium sulfate IV) rather than by the specific co-formulated vehicle (D5W) and container type (plastic).
• As a result, the most visible clinical evidence in public registries is not consistently tagged to “MgSO4 in D5% in plastic container,” limiting the ability to produce a precise, product-identical trial update for this exact formulation.

Most common trial clusters by indication

1. Severe preeclampsia/eclampsia and obstetric magnesium regimens

   • Trials generally compare magnesium sulfate dosing strategies (loading dose, maintenance infusion duration, bolus vs infusion, therapeutic monitoring thresholds) and safety outcomes.
   • Dextrose vs saline comparators may appear indirectly where IV compatibility or concomitant regimens are standardized, but not always tracked under the exact “magnesium sulfate in D5W” label.

2. Cardiac arrhythmia rescue (torsades de pointes) and QT prolongation contexts

   • Magnesium sulfate is frequently used as acute therapy; trials may focus on dosing strategies and comparative approaches around QT management.

3. Hypomagnesemia correction protocols

   • Trials evaluate infusion rates, target magnesium levels, monitoring approaches, and transition from IV to oral therapy.

How to read a “format” in trial disclosures

• For older, widely used IV generics, many clinical protocols use “magnesium sulfate injection” without a persistent link to the commercial vehicle or container. Container material can affect compatibility and extractables, but it is rarely the clinical endpoints driver.

Is Magnesium Sulfate in Dextrose 5% FDA-approved and what is the Orange Book status?

Orange Book status

• This question requires product-level mapping: the Orange Book lists NDA/ANDA entries for specific strengths and dosage forms. The FDA “Orange Book” status for “magnesium sulfate in dextrose 5%” depends on each specific ANDA/NDA listing.
• Without the exact ANDA/NDA identifiers and strength/container configuration from Orange Book listings, a complete, accurate “status of the drug” cannot be produced for this exact market descriptor.

FDA labeling dimensions that matter commercially

• Indication coverage in label language drives hospital adoption more than packaging type.
• Container type is relevant to IV administration workflows and compatibility but usually not the gating factor for clinical use.

What patents protect magnesium sulfate IV solutions in D5W, and how strong is the patent estate?

Patent estate reality for this category

• Magnesium sulfate is a long-established active ingredient with broad generic availability. For mature IV solutions, the patent landscape commonly consists of:
  • old composition/process patents long expired,
  • formulation or container-related patents that may vary by applicant,
  • late-life patents only in certain branded or niche presentations.

What that means for “in D5W in plastic container”

• Protection, where it exists, is typically not centered on the active ingredient, but on:
  • specific concentration ranges,
  • manufacturing process constraints,
  • stability/compatibility claims,
  • container-closure system claims for plastic bags or prefilled infusion devices.

Actionable implication

• For licensing or challenge strategy, the practical value comes from identifying patent listings tied to the specific ANDA/NDA entry and then mapping to container and strength. A generic “MgSO4 in D5W plastic” basket search is insufficient for legal precision.

When does exclusivity expire for Magnesium Sulfate in Dextrose 5% in plastic container?

Exclusivity drivers

• Market exclusivity (3-year, 5-year, pediatric extensions) applies at the NDA/ANDA application level, not to a generic product description.
• Most magnesium sulfate IV solutions are expected to be beyond exclusivity due to age of the active and standard manufacturing.

What is required to answer precisely

• The exclusivity timeline must be tied to a specific Orange Book listing (NDA/ANDA number) and relevant exclusivity codes. Without those identifiers, any “expiration date” would be non-actionable.

What generic entry risks exist for Magnesium Sulfate in Dextrose 5% (D5W) IV solutions?

Main entry barriers

1. Manufacturing reliability

   • Maintaining solution stability and preventing precipitation or compatibility issues with concomitant IV therapies is a critical barrier in IV solutions.

2. Supply and shortages

   • In many IV categories, the fastest barrier is not patents but supply capacity, raw material procurement, and quality-system throughput.

3. Container-closure compatibility

   • For prefilled plastic bags, extractables/leachables control and shelf-life stability under defined storage conditions can affect approvals and commercialization timelines.

Practical generic launch scenario (high level)

• For this category, generics typically launch when approvals clear and supply chains stabilize. Patent-driven launches are less frequent than in new therapeutics.

How does Magnesium Sulfate in Dextrose 5% compare with Magnesium Sulfate in Normal Saline for hospitals?

Clinical equivalence depends on indication

• In obstetric and critical care protocols, magnesium sulfate efficacy is driven by serum magnesium, not by the vehicle, assuming standard dosing and compatibility.
• D5W may be preferred when patients require dextrose or when it aligns with IV fluid management protocols. Normal saline may be preferred when fluid composition constraints exist.

Operational drivers

• Pharmacy stock rationalization often favors the formulation most commonly used in local protocols.
• Substitution between D5W and NS is constrained by institutional protocols and nursing compatibility workflows.

What market does this drug serve and how large is demand?

Demand centers

1. Obstetrics

   • MgSO4 is a cornerstone therapy in severe preeclampsia and eclampsia.
   • Demand tracks with obstetric incidence, guideline adherence, and hospital delivery volume.

2. ICU and emergency

   • Torsades de pointes rescue and hypomagnesemia correction are common use cases.
   • Demand tracks with ICU throughput, arrhythmia caseloads, and electrolyte management protocols.

3. Hospital pharmacy utilization

   • IV magnesium is often a standardized standing-order item in emergency and obstetric units.

Market size and growth projection

• A reliable market model needs:
  • country/region scope,
  • unit strengths (for example, MgSO4 concentration and infusion volume),
  • number of eligible administrations or mg delivered per patient.
• Without those parameters and without cited market data in the request payload, providing numerical market size and forecast would not be defensible.

What are the pricing dynamics and reimbursement patterns for MgSO4 in D5W IV solutions?

Pricing dynamics

• Competitive pressure is typically high due to generic availability and commodity-like supply.
• Pricing tends to be sensitive to:
  • energy and raw-material costs (manufacturing scale),
  • container supply (plastic bag availability),
  • episodic shortages.

Reimbursement

• IV solutions are usually reimbursed through hospital purchasing contracts and formularies rather than distinct drug-specific reimbursement premium, given their staple status.

Which companies supply Magnesium Sulfate in Dextrose 5% in plastic containers?

A company-by-company supplier list requires:

• product-level identification (strength, label claims, container type),
• country-specific market mapping,
• and/or FDA label/ANDA data extraction.

Without those identifiers and without cited source material, listing specific companies would risk incorrect attribution.

What supply-chain and manufacturing/IP barriers could affect future availability?

Supply chain

• IV solution availability is often constrained by:
  • raw magnesium sulfate supply,
  • dextrose supply,
  • plastic container supply chain,
  • sterile manufacturing capacity.

Quality/regulatory

• Batch release stability and sterility assurance can slow scale-up during demand spikes.

IP

• For mature magnesium sulfate solutions, IP barriers are generally not the dominant determinant of new supply entry.

How will clinical guidelines affect utilization of magnesium sulfate in D5W?

Guideline impact channels

• Updates that reinforce magnesium sulfate use in eclampsia and severe preeclampsia stabilize demand.
• Protocol changes in infusion monitoring, duration, and therapeutic thresholds can shift utilization intensity but rarely reduce overall demand meaningfully for core indications.

Research impact channel

• Clinical trials that establish dosing safety and monitoring approaches can influence adoption of local protocols.
• Trials that focus on vehicle effects are uncommon in this product class.

What litigation or patent challenges affect magnesium sulfate IV solutions?

Patent litigation for a mature generic IV product class is often limited and not consistently tied to “MgSO4 in D5W” phrasing. A complete “what litigation affects this drug” answer must be anchored to:

• specific Orange Book-listed patents and ANDA litigation dockets,
• or specific settlement/consent decree documents.

Without those anchors, providing a docket-level litigation update would not be accurate.

Market forecast: base case, bull case, and bear case for MgSO4 in D5W plastic

Forecast approach for this category

• Because product-level trial catalysts are limited, the forecast is best modeled as:
  • demand for magnesium sulfate administrations driven by obstetric and ICU incidence,
  • adjusted for substitution between D5W and NS,
  • adjusted for procurement volatility during supply disruptions.

Scenario drivers

• Base case: steady incidence and guideline-driven utilization, stable generic supply.
• Bull case: increased adoption of standardized magnesium protocols and improved access in delivery and emergency settings; supply improves and reduces stockouts.
• Bear case: persistent supply constraints and increased substitution away from D5W due to local fluid management policies or contracting shocks.

Numerical projection requirement

• Numeric forecasts require unit-level and geography-specific baseline data plus documented utilization patterns. Those inputs are not provided in the request, and no cited market datasets are available within the provided context.

Key Takeaways

• Clinical evidence exists for magnesium sulfate therapy, but public trial disclosures often do not map cleanly to the exact formulation “in D5W in plastic container,” limiting format-specific trial updates.
• Exclusivity, Orange Book status, and patent protection must be tied to specific NDA/ANDA listings; a descriptive product name is insufficient for legally and commercially actionable timelines.
• Market demand is driven by obstetric (severe preeclampsia/eclampsia) and acute care (torsades rescue, hypomagnesemia correction) utilization more than by container-vehicle nuances.
• Forecasting should rely on utilization proxies and supply stability rather than trial-driven growth expectations typical of newer therapeutics.

FAQs

1. How do hospitals decide between magnesium sulfate in D5W vs magnesium sulfate in normal saline for obstetric protocols?
2. What regulatory submissions are typically required to market an IV magnesium sulfate solution in a plastic container?
3. Do container-closure systems for IV bags create product differentiation that affects exclusivity or approval timing?
4. How does magnesium sulfate shortage history influence procurement strategies for hospital systems?
5. What endpoints matter most in clinical protocols comparing magnesium sulfate dosing regimens in severe preeclampsia?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. ClinicalTrials.gov. Magnesium sulfate clinical studies by indication. U.S. National Library of Medicine.